drugset / Trial / NCT00407095
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-05
- Completion
- 2009-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pardoprunox | Small molecule | 12 mg | — |
| Subject | Pardoprunox | Small molecule | 42 mg | — |